Transmission of COVID-19 in Nightlife, Household, and Health Care Settings in Tokyo, Japan, in 2020.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
01 02 2023
Historique:
entrez: 24 2 2023
pubmed: 25 2 2023
medline: 3 3 2023
Statut: epublish

Résumé

There have been few studies on the heterogeneous interconnection of COVID-19 outbreaks occurring in different social settings using robust, surveillance epidemiological data. To describe the characteristics of COVID-19 transmission within different social settings and to evaluate settings associated with onward transmission to other settings. This is a case series study of laboratory-confirmed COVID-19 cases in Tokyo between January 23 and December 5, 2020, when vaccination was not yet implemented. Using epidemiological investigation data collected by public health centers, epidemiological links were identified and classified into 7 transmission settings: imported, nightlife, dining, workplace, household, health care, and other. The number of cases per setting and the likelihood of generating onward transmissions were compared between different transmission settings. Of the 44 054 confirmed COVID-19 cases in this study, 25 241 (57.3%) were among male patients, and the median (IQR) age of patients was 36 (26-52) years. Transmission settings were identified in 13 122 cases, including 6768 household, 2733 health care, and 1174 nightlife cases. More than 6600 transmission settings were detected, and nightlife (72 of 380 [18.9%]; P < .001) and health care (119 [36.2%]; P < .001) settings were more likely to involve 5 or more cases than dining, workplace, household, and other settings. Nightlife cases appeared in the earlier phase of the epidemic, while household and health care cases appeared later. After adjustment for transmission setting, sex, age group, presence of symptoms, and wave, household and health care cases were less likely to generate onward transmission compared with nightlife cases (household: adjusted odds ratio, 0.03; 95% CI, 0.02-0.05; health care: adjusted odds ratio, 0.57; 95% CI, 0.41-0.79). Household settings were associated with intergenerational transmission, while nonhousehold settings mainly comprised transmission between the same age group. Among 30 932 cases without identified transmission settings, cases with a history of visiting nightlife establishments were more likely to generate onward transmission to nonhousehold settings (adjusted odds ratio, 5.30 [95% CI, 4.64-6.05]; P < .001) than those without such history. In this case series study, COVID-19 cases identified in nightlife settings were associated with a higher likelihood of spreading COVID-19 than household and health care cases. Surveillance and interventions targeting nightlife settings should be prioritized to disrupt COVID-19 transmission, especially in the early stage of an epidemic.

Identifiants

pubmed: 36826818
pii: 2801819
doi: 10.1001/jamanetworkopen.2023.0589
pmc: PMC9958531
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e230589

Références

N Engl J Med. 2022 Oct 27;387(17):1620-1622
pubmed: 36198139
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
Am J Ophthalmol. 2011 Jan;151(1):7-10.e1
pubmed: 21163373
JMIR Public Health Surveill. 2021 Apr 6;7(4):e22880
pubmed: 33690143
Proc Natl Acad Sci U S A. 2020 Sep 8;117(36):22430-22435
pubmed: 32820074
Front Immunol. 2021 Oct 06;12:744696
pubmed: 34691049
JAMA Pediatr. 2022 Aug 1;176(8):811-813
pubmed: 35363246
Science. 2021 Feb 5;371(6529):
pubmed: 33303686
Emerg Infect Dis. 2020 Oct;26(10):2499-2501
pubmed: 32633713
Elife. 2021 Apr 16;10:
pubmed: 33861198
Front Public Health. 2021 Feb 26;9:625778
pubmed: 33718322
MMWR Morb Mortal Wkly Rep. 2020 Sep 11;69(36):1258-1264
pubmed: 32915165
Nature. 2021 Jan;589(7840):82-87
pubmed: 33171481
Front Psychol. 2021 Apr 01;12:643653
pubmed: 33868115
N Engl J Med. 2022 Nov 10;387(19):1770-1782
pubmed: 36286260
Wellcome Open Res. 2020 Apr 9;5:67
pubmed: 32685698
Clin Infect Dis. 2005 Feb 1;40(3):366-73
pubmed: 15668858
Science. 2021 Mar 26;371(6536):
pubmed: 33531384
N Engl J Med. 1995 Jul 27;333(4):222-7
pubmed: 7791838
Euro Surveill. 2015 Jun 25;20(25):7-13
pubmed: 26132767
Euro Surveill. 2021 Dec;26(50):
pubmed: 34915975
mSphere. 2020 Nov 11;5(6):
pubmed: 33177213
Science. 2021 Jan 15;371(6526):
pubmed: 33234698
Proc Natl Acad Sci U S A. 2021 Apr 6;118(14):
pubmed: 33741734
JAMA Netw Open. 2022 Apr 1;5(4):e229317
pubmed: 35482308
Nat Commun. 2020 Oct 6;11(1):5006
pubmed: 33024095
Nat Commun. 2021 Oct 5;12(1):5820
pubmed: 34611158
Emerg Infect Dis. 2022 May;28(5):1012-1016
pubmed: 35271792
R Soc Open Sci. 2020 Sep 23;7(9):200786
pubmed: 33047040
JMA J. 2021 Jul 15;4(3):198-206
pubmed: 34414313
Nat Microbiol. 2022 Aug;7(8):1161-1179
pubmed: 35798890
Proc Natl Acad Sci U S A. 2020 Jul 7;117(27):15530-15535
pubmed: 32554604
Emerg Infect Dis. 2022 Sep;28(9):1856-1858
pubmed: 35914518
PLoS Med. 2022 Mar 1;19(3):e1003907
pubmed: 35231023
Influenza Other Respir Viruses. 2022 Sep;16(5):952-961
pubmed: 35470969
Am J Public Health. 2022 Jan;112(1):169-178
pubmed: 34936403
J Infect. 2021 Jan;82(1):36-40
pubmed: 33245943
MMWR Morb Mortal Wkly Rep. 2003 May 9;52(18):405-11
pubmed: 12807088

Auteurs

Takeaki Imamura (T)

Department of Virology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Aika Watanabe (A)

Itabashi-City Public Health Center, Tokyo, Japan.

Yusuke Serizawa (Y)

National Defense Medical College Hospital, Saitama, Japan.

Manami Nakashita (M)

National Institute of Infectious Diseases, Tokyo, Japan.

Mayuko Saito (M)

Department of Virology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Mayu Okada (M)

Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.

Asamoe Ogawa (A)

Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.

Yukiko Tabei (Y)

Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.

Yoshiko Soumura (Y)

Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.

Yoko Nadaoka (Y)

Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.

Naoki Nakatsubo (N)

Public Health and Disease Prevention Division, Suginami City Public Health Center, Tokyo, Japan.

Takashi Chiba (T)

Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.

Kenji Sadamasu (K)

Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.

Kazuhisa Yoshimura (K)

Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.

Yoshihiro Noda (Y)

Department of Plastic, Reconstructive and Aesthetic Surgery, Nippon Medical School, Tokyo, Japan.

Yuko Iwashita (Y)

Tama Tachikawa Public Health Center, Tokyo, Japan.

Yuji Ishimaru (Y)

Bureau of Social Welfare and Public Health, Tokyo Metropolitan Government, Tokyo, Japan.

Naomi Seki (N)

Ota City Public Health Center, Tokyo, Japan.

Kanako Otani (K)

National Institute of Infectious Diseases, Tokyo, Japan.

Tadatsugu Imamura (T)

National Center for Child Health and Development, Tokyo, Japan.

Matthew Myers Griffith (MM)

National Centre for Epidemiology and Population Health, the Australian National University, Canberra, Australia.

Kelly DeToy (K)

Division of Global Disease Epidemiology and Control, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

Motoi Suzuki (M)

National Institute of Infectious Diseases, Tokyo, Japan.

Michihiko Yoshida (M)

Minato Public Health Center, Tokyo, Japan.

Atsuko Tanaka (A)

Bureau of Social Welfare and Public Health, Tokyo Metropolitan Government, Tokyo, Japan.

Mariko Yauchi (M)

Bunkyo-City Public Health Center, Tokyo, Japan.

Tomoe Shimada (T)

National Institute of Infectious Diseases, Tokyo, Japan.

Hitoshi Oshitani (H)

Department of Virology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH